Literature DB >> 16874683

Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response.

Peter Ochodnicky1, Simone Vettoretti, Robert H Henning, Hendrick Buikema, Richard P E Van Dokkum, Dick de Zeeuw.   

Abstract

Endothelial dysfunction (ED) seems to be a crucial mediator of increased cardiovascular risk observed among patients with chronic kidney disease (CKD). Importantly, systemic ED does not only occur in patients with severe renal failure, but also in individuals with earlier stages of CKD. Close association between microalbuminuria and systemic ED renders renal vascular function an important marker for the severity of cardiovascular damage. Furthermore, changes in renal endothelium might be actively involved in the progression of renal end-organ damage. Recently, experimental evidence showed that interindividual variability in endothelial function of healthy rats predicts susceptibility to renal damage and the efficacy of renoprotective treatment. Therefore, a specific manipulation of renal and systemic ED might provide benefits in various stages of CKD. ED thus may represent an ideal therapeutic target not only for treatment, but also for primary prevention of renal disease.

Entities:  

Mesh:

Year:  2006        PMID: 16874683

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  18 in total

1.  Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress.

Authors:  Mina Yu; Young Ju Kim; Duk-Hee Kang
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

2.  Ascorbic acid or L-arginine improves cutaneous microvascular function in chronic kidney disease.

Authors:  Jennifer J Dupont; William B Farquhar; Raymond R Townsend; David G Edwards
Journal:  J Appl Physiol (1985)       Date:  2011-09-01

3.  The Effect of Admission Renal Function on the Treatment and Outcome of Patients with Acute Coronary Syndrome.

Authors:  Zach Rozenbaum; Sydney Benchetrit; Saar Minha; Yoram Neuman; Meital Shlezinger; Ilan Goldenberg; Morris Mosseri; David Pereg
Journal:  Cardiorenal Med       Date:  2017-02-17       Impact factor: 2.041

Review 4.  Is reversal of endothelial dysfunction still an attractive target in modern cardiology?

Authors:  Ify Mordi; Nikolaos Tzemos
Journal:  World J Cardiol       Date:  2014-08-26

5.  Endothelial dysfunction in uremic patients on continuous ambulatory peritoneal dialysis (CAPD).

Authors:  Senija Rašić; Almira Hadžović-Džuvo; Damir Rebić; Amina Valjevac; Snežana Unčanin
Journal:  Bosn J Basic Med Sci       Date:  2011-08       Impact factor: 3.363

6.  Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease.

Authors:  Mehmet Kanbay; Mahmut Ilker Yilmaz; Alper Sonmez; Faruk Turgut; Mutlu Saglam; Erdinc Cakir; Mujdat Yenicesu; Adrian Covic; Diana Jalal; Richard J Johnson
Journal:  Am J Nephrol       Date:  2011-03-08       Impact factor: 3.754

7.  Prognostic value of serum von Willebrand factor, but not soluble ICAM and VCAM, for mortality and cardiovascular events is independent of residual renal function in peritoneal dialysis patients.

Authors:  Jie Dong; Yan-Jun Li; Zhi-Kai Yang; Rong Xu
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

8.  Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet.

Authors:  Sarah F Knight; Jeffrey E Quigley; Jianghe Yuan; Siddhartha S Roy; Ahmed Elmarakby; John D Imig
Journal:  Hypertension       Date:  2007-12-24       Impact factor: 10.190

9.  Vitamin d receptor activation mitigates the impact of uremia on endothelial function in the 5/6 nephrectomized rats.

Authors:  J Ruth Wu-Wong; William Noonan; Masaki Nakane; Kristin A Brooks; Jason A Segreti; James S Polakowski; Bryan Cox
Journal:  Int J Endocrinol       Date:  2010-02-10       Impact factor: 3.257

10.  Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats.

Authors:  John D Imig; Katie A Walsh; Md Abdul Hye Khan; Tasuku Nagasawa; Mary Cherian-Shaw; Sean M Shaw; Bruce D Hammock
Journal:  Exp Biol Med (Maywood)       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.